Clinically, patients report greater satiety and reduced hunger, even during significant weight loss
Initially approved for the treatment of Type 2 diabetes, its benefits have extended beyond just controlling blood glucose levels and obesity treatment
Repurposing of long-acting FDA-approved GLP-1 receptor agonists such as semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple-agonist retatrutide which additionally targets glucagon receptors and is currently in clinical trials for obesity, may offer a promising strategy treating AUD
Wegovy 0.5mg Injection - 1 Month Supply Weight LossIn stock Wegovy 0.5mg Injection - 1 Month Supply Weight LossIn stock What is Wegovy Wegovy is a weight loss and maintenance medicine containing the active substance Semaglutide
However, the incidence of ED in males who take semaglutide needs further study
Must be discontinued at least 2 full months before planning a pregnancy to clear the peptide